ZEJULA ▼ (niraparib) logo

Product menu

Image of fictitious patient
Quality of life (QoL) with ZEJULA
Preservation of quality of life icon

QoL preserved
for over 30 cycles of ZEJULA maintenance vs placebo1,2

VIEW QOL

Reduced fatigue icon

Reduced long-term fatigue
in ZEJULA patients vs placebo3,4

VIEW FATIGUE

Quality of life in the long term

ZEJULA preserved QoL in women with advanced ovarian cancer over 30 cycles of maintenance therapy‡2

Health-related QoL/patient-reported outcomes*‡

A graph showing health-related QoL/patient-reported outcomes A graph showing health-related QoL/patient-reported outcomes

Figure adapted from González-Martín A, et al. 2019

This analysis is exploratory in nature and does not control for Type 1 error; elements more distal to disease and treatment-related symptoms may be influenced by multiple nondrug factors.2

FOSI QoL domains included: mobility, self-care, anxiety/depression, pain/discomfort and usual activities.

*A treatment cycle lasted 28 days
‡FOSI (Functional Assessment of Cancer Therapy-Ovarian Symptoms Index) is a validated 8-item measure of symptom response to treatment, including lack of energy, vomiting, pain, nausea, stomach swelling, worsening condition, quality of life as assessed by the patient, and cramps in the stomach area.2,5

Discover the efficacy of ZEJULA in PRIMA

EXPLORE EFFICACY

Long-term fatigue

ZEJULA reduced the burden of long-term fatigue common among advanced ovarian cancer patients vs placebo3,4

EORTC QLQ-30 endpoint3

A graph showing long-term fatigue in overall population A graph showing long-term fatigue in overall population

Figure adapted from Halla K, et al. 2020

Post-surgical patients reported an improvement in fatigue over more than 15 treatment cycles of ZEJULA vs placebo§3

§The analysis was exploratory in nature and did not control for Type 1 error; elements more distal to disease and treatment-related symptoms may have been influenced. In the PRIMA trial, a treatment cycle lasted 28 days.3

Learn more about ZEJULA

Efficacy

See ZEJULA efficacy in PRIMA

MoA

See ZEJULA’s mechanism of action

Safety

See ZEJULA safety in PRIMA

ZEJULA is indicated:6

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Footnotes

EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; FOSI, Functional Assessment of Cancer Therapy-Ovarian Symptoms Index; MoA, mechanism of action; QoL, quality of life; SE, standard error.

References

  1. González-Martín A, Pothuri B, Vergote I, et al. N Engl J Med. 2019;381(25):2391–2402.
  2. Gonzalez-Martin A, et al. N Engl J Med. 2019; 381: 2391–2402. Supplementary appendix.
  3. Halla K, et al. Presented at the Oncology Nursing Society 45th Annual Congress, April 29–May 3, 2020, San Antonio, Texas. 
  4. Joly F, et al. Study. Annals of Oncology, 2019; DOI: 10.1093/annonc/mdz074.
  5. FACIT.org. Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 8 item version. Available at: https://www.facit.org/measure-english-downloads/fosi-english-downloads. Last accessed: April 2022
  6. ZEJULA Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

October 2022 | PM-GB-NRP-WCNT-220016 (V1.0)

February 2022 | PM-GB-NRP-WCNT-210016 v1.0